Remove 2019 Remove Competition Remove Doctors
article thumbnail

Collaborations between pharma and academia increase

European Pharmaceutical Review

The benefits of exposing students to the industry this way enables both parties to share knowledge, experience and provides students networking opportunities that can be difficult to obtain for such a competitive industry, said ABPI. It also found that The University of Bath, UK hosted the most industry placements: 61 in 2019 and 2022.

Pharma 104
article thumbnail

Pharma’s reputational high will be short-lived

World of DTC Marketing

Big Pharma’s reputation has been down in the dumps for years, after a series of scandals involving Medicare fraud, improper payments to doctors, and poorly tested drugs that damaged health. Pharma has gone to court again and again to delay generic competition of biologic drugs. In fact, Richard Gonzalez, C.E.O.

Pharma 186
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Biogen’s Alzheimer’s drug: What’s the price tag on hope?

World of DTC Marketing

Since that time, Biogen’s MS drugs have faced intense competition as MS patients continue to vent on social media that the Biogen drug has nasty side effects. Too many doctors, the data was still questionable. After the CEO departed the sinking ship, new management pinned all their hopes on the Biogen drug for Alzheimer’s.

FDA 187
article thumbnail

How to Adapt Your Marketing Now That Private Practice Has Become an “Endangered Species”

Healthcare Success

According to Avalere Health , nearly three in four doctors work for a hospital, health system, or corporate entity today. Since the start of the pandemic, tens of thousands of doctors have abandoned their privately-owned medical practices in favor of working in a hospital or larger medical group. . In other words, only 26.1%

article thumbnail

Katie Porter attacks pharma

World of DTC Marketing

The cost of bringing a drug to market decreased from $2,168 million in 2018 to $1,981 in 2019. Then there are ever increasing health insurance and hospital costs at a time when less people are going to the doctor’s office because of COVID-19. In pharma R&D returns have declined to 1.8 percent—a slight decrease of 0.1

Pharma 187
article thumbnail

Patient growth strategies for optimizing volume and value

Clarify Health

Here’s a recap on the current market challenges that leading health systems are facing and the effective strategies they are using today in order to stay ahead of tomorrow’s competition: In today’s ever-shifting consumer landscape, it’s crucial to understand the needs of your market(s) if you want to attract and retain patients.

article thumbnail

How AI Can Help Medical Science Liaisons Juggle Their Ever-Growing Responsibilities

PM360

1 And, on average , the FDA approved 60% more drugs between 2010-2019 than the yearly average over the previous decade. Orchestrated omnichannel engagement has grown into a buzz phrase for commercial teams ever since they started using digital communications channels to engage with doctors.